期刊文献+

自噬途径对反式-BPDE诱导人支气管上皮细胞16HBE影响及其机制的探讨 被引量:1

Role of autophagy in the malignant transformation of 16HBE cells by anti-BPDE
原文传递
导出
摘要 目的:研究反式-BPDE诱导正常的人支气管上皮细胞16HBE发生恶性转化前后自噬水平的变化及其可能机制。方法:利用前期建立的细胞恶性转化模型,采用激光共聚焦扫描显微镜成像技术,在无损伤状态下,实时观测反式-BPDE恶性转化细胞(16HBE-T)和正常细胞(16HBE-N)中自噬体标记蛋白GFP-LC3的荧光强度及定位,并利用蛋白质印迹法技术检测细胞内自噬信号通路关键效应分子的表达。结果:16HBE-T细胞与16HBE-N细胞相比,GFP-LC3蛋白的点状聚集明显减少,只有16HBE-N细胞的1/3左右,表明自噬水平下降,蛋白质印迹法检测发现,mTOR激酶活性上升,Beclin 1表达下降。结论:反式-BPDE可能通过自噬途径参与诱导16HBE细胞恶性转化的癌变过程,将为预防和治疗肺癌提供重要信息。 OBJECTIVE:To investigate the mechanism of autophagy-related signaling pathway in the anti-BPDE trans- formed 16 HBE (16 Ht^E-T) cells, and find new access for prevention and treatment of lung cancer. METHODS: By using of the pre-established model of malignant transformation of cells, we monitored the position and fluorescence intensity of the GFP-LC3 protein that was used to show autophagy in living cells with confoeal laser scanning microscopy imaging. We also detect the chan- ges of autophagy in the normal 16HBE (16HEE-N) and malignant transformed cells (16HBE-T) with Western blotting. RE- SULTS:Compared with that of 16HBE-N ceils, the GFP-LC3 protein punctuate aggregation of 16HBE-N cells significantly re- duced to 1/3 amount of 16HBE-N cells,suggesting that autocracy levels declinded. At the same time,the roTOR kinase activity and Beclin 1 expression were found to be increased and decreased, respectively. CONCLUSION: This experiment demonstrates that autophagy involves in the malignant transformation induced by anti-BPDE via multiple pathways, and the study of autophagy will be great benefit for the prevention and treatment of lung cancer.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第12期885-887,共3页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(81102159 81072366 30872178) 广东省自然科学基金博士启动项目(S2011040003622) 广东省高层次人才项目(2010-79) 广东高校优秀青年创新人才培养计划项目(2009) 广州市科技和信息化局应用基础研究计划项目(2012J4100-016)
关键词 肺肿瘤 自吞噬作用 Bedim基因 lung neoplasms autophagocytosis genes,Beclin 1
  • 相关文献

参考文献3

二级参考文献31

  • 1吴中亮,陈家,詹德进,何玲,杜应秀,Joseph M.Wu.苯并a芘对人胎气管上皮细胞生物大分子作用的探讨[J].肿瘤,1996,16(5):520-524. 被引量:3
  • 2高立,孙海娅,杨本付.尼古丁成瘾的相关因素分析[J].长江大学学报(自科版)(下旬),2007,4(1):98-100. 被引量:4
  • 3Amos C I, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1[J]. Nat Genet, 2008, 40(5):616-622.
  • 4Hung R J, McKay J D, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25[J]. Nature, 2008, 452(7187):633-637.
  • 5Thorgeirsson T E, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease[J]. Nature, 2008, 452(7187):638-642.
  • 6Wu C, Hu Z, Yu D, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations[J]. Cancer Res, 2009, 69(12):5065-5072.
  • 7Shields P G. Epidemiology of tobacco carcinogenesis[J]. Curr Oncol Rep, 2000, 2(3):257-262.
  • 8Minna J D. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer[J]. J ClinInvest, 2003, 111(1):31-33.
  • 9Schuller H M. Nitrosamines as nicotinic receptor ligands[J]. Life Sci, 2007, 80(24-25):2274-2280.
  • 10West K A, Brognard J, Clark A S, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells[J]. J Clin Invest, 2003, 111(1) :81-90.

共引文献72

同被引文献15

  • 1Pao W,Chmielecki J. Rational,biologically based treatment of EGFRmutant non-small-cell lung cancer[J].Nature Reviews Cancer,2010,(11):760-774.
  • 2Stella GM,Luisetti M,Inghilleri S. Targeting EGFR in nonsmall-cell lung cancer:lessons,experiences,strategies[J].Respiratory Medicine,2012,(02):173-183.
  • 3Giaccone G,Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors[J].Cancer Treatment Reviews,2011,(06):456-464.
  • 4Oxnard GR,Arcila ME,Chmielecki J. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer[J].Clinical Cancer Research,2011,(17):5530-5537.
  • 5Guo R,Chen X,Wang T. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores re sponse to tyrosine kinase inhibitor in advanced non small-cell lung cancer[J].BMC Cancer,2011.90.
  • 6Kaira K,Yamamoto N. Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer[J].Onkologie,2012,(1-2):8-9.
  • 7Takeda M,Okamoto I,Tsurutani J. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFRTKI in EGFR-mutated NSCLC[J].Japanese Journal of Clinical Oncology,2012,(06):528-533.
  • 8He C,Liu M,Zhou C. Detection of epidermal growth factorreceptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-smallcell lung cancer[J].International Journal of Cancer,2009,(10):2393-2399.
  • 9Pennell NA. Integration of EGFR inhibitors and conventional chemo therapy in the treatment of non-small-cell lung cancer[J].Clinical Lung Cancer,2011,(06):350-359.
  • 10Mok TS,Wu YL,Yu CJ. Randomized,placebo-controlled,phase Ⅱ study of sequential erlotinib and chemotherapy as firstline treatment for advanced non-small-cell lung cancer[J].Journal of Clinical Oncology,2009,(30):5080-5087.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部